Cases Of Adjacent Non-tumor Tissues Research Articles

High level of lncRNA H19 expression is associated with shorter survival in esophageal squamous cell cancer patients

AimLong non-coding RNA (lncRNA) is currently considered to play an important regulatory role in various diseases, including tumors, at present a hot topic in research. As a non-coding transcription product of imprinted gene, LncRNA H19 is expressed as a parent imprinted maternal allele without protein-coding ability. Increasing evidence indicates that LncH19 may be a new tumor marker for early clinical diagnosis and prognosis judgment. In this study, LncH19 expression was investigated by RNA in situ hybridization for further exploring the clinicopathological role of its expression in esophageal squamous cell cancer (ESCC). Methods121 tumor samples and seven cases of adjacent non-tumor tissues from esophageal cancer patients were detected by RNA in situ hybridization (ISH) and the ISH staining was graded with modified Allred scoring. ResultsWhile no LncH19 expression in the tumor adjacent to normal epithelia was disclosed with the technology, significantly higher levels of LncH19 expression were detected in the tumors obtained from the patients who died within one year after surgery, compared to the expression in those tumors from the patients who survived longer than five years after the same treatment regimen (P = 0.001). In addition, LncH19 expression was verified to correlate with a larger tumor size (P = 0.002) and a higher UICC stage (P = 0.001). ConclusionOur LncH19 ISH data verify the involvement of LncH19 in ESCC. Higher levels of LncH19 expression were not only detected in tumors with larger size and in clinical late stage, but also significantly associated with shorter survival, strongly indicating its clinical significance in the malignant progression of ESCC and useful value as a poor prognostic factor for the patients.

Expression of microRNA-30b-5p in prostate cancer and its effects on proliferation of prostate cancer cells

Objective To explore the expression of microRNA (miRNA, miR)-30b-5p in prostate cancer (PCa) and its impact on prostate cancer cells. Methods The expression of miR-30b-5p in 41 cases of PCa tissues and 41 cases of adjacent non-tumor tissues was detected by real-time quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR). The relationship between the expression of miR-30b-5p and clinicopathological features was analyzed. Human prostate cancer PC-3 cells were divided into three groups: control group, negative control group and over-expression group. The expression of miR-30b-5p in PC-3 cells was detected by RT-qPCR. The cell proliferation was measured by cell counting kit-8 (CCK-8) assay and colony formation and anchorage-independent growth assay. The protein expression of proliferation cell nuclear antigen (Ki-67), β-catenin and Cyclin D1 was detected by Western blotting. Results The expression of miR-30b-5p in prostate cancer tissues (0.469±0.032) was significantly lower than that in adjacent tissues (0.997±0.016) (t=14.499, P=0.000). In addition, the rate of low miR-30b-5p expression in clinical state Ⅲ-Ⅳ [65.2% (15/23) vs. 33.3% (6/18), χ2=4.108, P=0.043], pathological grading G3-G4 [72.7% (16/22) vs. 26.3% (5/19), χ2=6.145, P=0.013] and Gleason scores ≥8 [72.0% (18/25) vs. 18.8% (3/16), χ2=11.072, P=0.001] groups were higher than those in clinical stage Ⅰ-Ⅱ, pathological grading G1-G2 and Gleason scores ≤7 groups. However, there were no difference in the rate of low miR-30b-5p expression in different age groups [54.5% (12/22) vs. 47.4% (9/19), χ2=0.210, P=0.647]. After transfection, the expression of miR-30b-5p in over-expression group (4.088±0.229) was higher than that in negative control group (1.028±0.054) (F=168.200, P=0.000). At 48 h and 72 h, the A450 in over-expression group measured by CCK-8 assay (0.308±0.040, 0.512±0.033) were lower than those in negative control group (0.494±0.035, 0.840±0.087) (F=6.514, P=0.001). The protein expressions of Ki-67, β-catenin and Cyclin D1 in negative control froup were 1.681±0.062, 1.067±0.188, 0.665±0.083. However, the protein expressions of them in over-expression group were remarkably decreased (Ki-67: 0.622±0.095, F=38.490, P=0.000; β-Catenin: 0.437±0.071, F=6.570, P=0.031; Cyclin D1: 0.237±0.049, F=13.510, P=0.006). Conclusion miR-30b-5p is low-expressed in prostate cancer cells, and over-expression of miR-30b-5p could inhibit the proliferation ability of prostate cancer cell, which may be related to the deactivation of Wnt/β-catenin signaling pathway. Key words: Prostate cancer; MicroRNA-30b-5p; Cell proliferation; Wnt/β-catenin signaling pathway

Expression and clinical significance of proline-rich tyrosine kinase 2 and phospho-protein kinase B in tongue squamous cell carcinoma

This study aimed to investigate the expression and clinical significance of proline-rich tyrosine kinase 2 (Pyk2) and phospho-protein kinase B (p-AKT) in tongue squamous cell carcinoma (TSCC) and adjacent nontumor tissues. The Pyk2 and p-AKT protein levels were detected via immunohistochemistry in 45 cases of TSCC tissues and 30 cases of adjacent nontumor tissues. The relationships of the two protein levels and clinicopathological characteristics were also analyzed. Pyk2 and p-AKT levels were significantly higher in the TSCC tissues than in the adjacent nontumor tissues (P<0.05). Nontumor tissues showed poor or no expression. The expression levels of the two proteins were positively correlated (γs=0.412). The expression of Pyk2 was associated with histopathological differentiation type, regional lymph node metastasis, and TNM staging (P<0.05), but not with age and gender. The expression of p-AKT was only related to histopathological differentiation types (P<0.05). The abnormal expression of Pyk2 and p-AKT proteins might be closely related to the development and progression of TSCC. Joint detection can be used as an indicator to estimate the degree of TSCC.

Prognostic significance of NADPH quinine oxidoreductase 1 overexpression in head and neck squamous cell carcinoma

To investigate the significance of NADPH quinine oxidoreductase 1 (NQO1) protein overexpression on prognostic evaluation of head and neck squamous cell carcinoma (HNSCC). NQO1 protein was detected in 162 of HNSCC, 45 cases of adjacent nontumor tissues and 26 samples of normal head and neck epithelia using EnVision immunohistochemical. Correlation between NQO1 overexpression and patients prognosis was also analyzed. The positive rate and strongly positive rate of NQO1 protein were 84.0% (136/162) and 69.8% (113/162) in HNSCC, respectively, and both of which were significantly higher than either those in adjacent nontumor tissues and normal head and neck epithelia (both P < 0.01). NQO1 expression was significantly correlated with the clinical stage, pT and chemoradiotherapy of HNSCC (P < 0.01). Kaplan-Meier survival analysis showed that overall survival and disease-free survival rates were significantly higher in HNSCC patients with high level NQO1 expression than that those with low level of NQO1 expression (Log-rank = 6.625 , P = 0.010;Log-rank = 6.234 , P = 0.013). Additional analysis by Cox proportional hazard regression model showed that high level of NQO1 expression was an independent hazard predictor for overall survival of patients with HNSCC (Wald = 6.626, P = 0.008). NQO1 expression level is closely correlated with the progression and prognosis of patients with HNSCC. High level of NQO1 expression may be used as an important indicator for patients with poor prognostic HNSCC.